ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
83,574.64
1.33%
S&P 500
5,670.97
0.67%
Dow Jones
42,225.32
0.56%
US Dollar vs Yen
147.6045
-0.22%
Brent Oil
73.225
-0.03%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Janux Therapeutics Inc (JANX)

  7. Janux Therapeutics Inc (JANX) ニュース

JANX

Janux Therapeutics (JANX)

Janux Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:JANX
日付受信時刻ニュースソース見出しコード企業名
2025/03/0610 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/03/0406 : 25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/02/2806 : 55Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:JANXJanux Therapeutics Inc
2025/02/2806 : 53Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:JANXJanux Therapeutics Inc
2025/02/2806 : 49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2025/02/2806 : 01Business WireJanux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsNASDAQ:JANXJanux Therapeutics Inc
2025/02/1506 : 41Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:JANXJanux Therapeutics Inc
2025/02/0610 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/02/0406 : 18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/2506 : 01Business WireJanux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical OfficerNASDAQ:JANXJanux Therapeutics Inc
2025/01/0910 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0806 : 11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0410 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0410 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0410 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0410 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0410 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0410 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0410 : 01Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:JANXJanux Therapeutics Inc
2025/01/0410 : 00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0407 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2025/01/0306 : 24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/12/2810 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/12/2700 : 00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/12/2108 : 25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
2024/12/0709 : 43Business WireJanux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 MillionNASDAQ:JANXJanux Therapeutics Inc
2024/12/0606 : 32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JANXJanux Therapeutics Inc
2024/12/0606 : 28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:JANXJanux Therapeutics Inc
2024/12/0513 : 12Business WireJanux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:JANXJanux Therapeutics Inc
2024/12/0410 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JANXJanux Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:JANX

最近閲覧した銘柄

AMEX
OMFS
Invesco Russell 2000 Dyn...
TSX
QQQX
Global X Nasdaq 100 Inde...
BIT
P1JYW6
BNP Paribas Issuance
NYSE
STVN
Stevanato
ASX
NSTCD
Northern Star Resources
NASDAQ
SPT
Sprout Social
FX
MWKEUR
MWK vs Euro
FX
SGDCZK
SGD vs CZK
BOV
CRFB3F
CARREFOUR ON
EU
SES5P
Euronext Sovereign Econo...
AQEU
ALME
Almirall
BITMOT
766950
Eib Green Bond Tf 1,25% ...
BOV
A2RR34
Arrowhead Pharmaceuticals
FX
NOKCNY
NOK vs CNY
BIT
P1TYH6
BNP Paribas Issuance
NYSE
LOMA
Loma Negra Compania Indu...
Delayed Upgrade Clock
ADVFN Logo
日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す